Marinus Pharmaceuticals Stock Buy Hold or Sell Recommendation
| MRNS Stock | USD 0.32 0.01 3.23% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Marinus Pharmaceuticals is 'Not Rated'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Marinus Pharmaceuticals given historical horizon and risk tolerance towards Marinus Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Marinus Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Marinus Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Marinus and provide practical buy, sell, or hold advice based on investors' constraints. Marinus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Marinus |
Execute Marinus Pharmaceuticals Buy or Sell Advice
The Marinus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Marinus Pharmaceuticals. Macroaxis does not own or have any residual interests in Marinus Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Marinus Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Marinus Pharmaceuticals Trading Alerts and Improvement Suggestions
| Marinus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Marinus Pharmaceuticals has high historical volatility and very poor performance | |
| Marinus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Marinus Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 30.99 M. Net Loss for the year was (141.41 M) with loss before overhead, payroll, taxes, and interest of (55.94 M). | |
| Marinus Pharmaceuticals currently holds about 168.25 M in cash with (118 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 83.0% of the company shares are owned by institutional investors |
Marinus Pharmaceuticals Returns Distribution Density
The distribution of Marinus Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Marinus Pharmaceuticals' future price movements. The chart of the probability distribution of Marinus Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Marinus Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Marinus Pharmaceuticals returns is essential to provide solid investment advice for Marinus Pharmaceuticals.
| Mean Return | -0.72 | Value At Risk | -9.76 | Potential Upside | 10.00 | Standard Deviation | 12.63 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Marinus Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Marinus Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Marinus Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Marinus Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Marinus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.04 | |
β | Beta against Dow Jones | 3.10 | |
σ | Overall volatility | 12.63 | |
Ir | Information ratio | -0.07 |
Marinus Pharmaceuticals Volatility Alert
Marinus Pharmaceuticals is displaying above-average volatility over the selected time horizon. Marinus Pharmaceuticals is a potential penny stock. Although Marinus Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Marinus Pharmaceuticals. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Marinus instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Marinus Pharmaceuticals Fundamentals Vs Peers
Comparing Marinus Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Marinus Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Marinus Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Marinus Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Marinus Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Marinus Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Marinus Pharmaceuticals to competition |
| Fundamentals | Marinus Pharmaceuticals | Peer Average |
| Return On Equity | -29.87 | -0.31 |
| Return On Asset | -0.58 | -0.14 |
| Operating Margin | (3.76) % | (5.51) % |
| Current Valuation | 30.86 M | 16.62 B |
| Shares Outstanding | 55.19 M | 571.82 M |
| Shares Owned By Insiders | 10.94 % | 10.09 % |
| Shares Owned By Institutions | 83.03 % | 39.21 % |
| Number Of Shares Shorted | 5.66 M | 4.71 M |
| Price To Earning | (4.80) X | 28.72 X |
| Price To Book | 3.17 X | 9.51 X |
| Price To Sales | 0.56 X | 11.42 X |
| Revenue | 30.99 M | 9.43 B |
| Gross Profit | (55.94 M) | 27.38 B |
| EBITDA | (125.5 M) | 3.9 B |
| Net Income | (141.41 M) | 570.98 M |
| Cash And Equivalents | 168.25 M | 2.7 B |
| Cash Per Share | 4.52 X | 5.01 X |
| Total Debt | 110.36 M | 5.32 B |
| Debt To Equity | 0.88 % | 48.70 % |
| Current Ratio | 8.41 X | 2.16 X |
| Book Value Per Share | 0.31 X | 1.93 K |
| Cash Flow From Operations | (118 M) | 971.22 M |
| Short Ratio | 1.09 X | 4.00 X |
| Earnings Per Share | (2.47) X | 3.12 X |
| Target Price | 1.47 | |
| Number Of Employees | 165 | 18.84 K |
| Beta | 1.26 | -0.15 |
| Market Capitalization | 17.05 M | 19.03 B |
| Total Asset | 170.91 M | 29.47 B |
| Retained Earnings | (571.93 M) | 9.33 B |
| Working Capital | 124.62 M | 1.48 B |
| Current Asset | 57.77 M | 9.34 B |
| Current Liabilities | 7.43 M | 7.9 B |
Note: Disposition of 1660 shares by Mayleben Timothy M of Marinus Pharmaceuticals subject to Rule 16b-3 [view details]
Marinus Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Marinus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Marinus Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Marinus Pharmaceuticals? Buying financial instruments such as Marinus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Marinus Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Entertainment Thematic Idea Now
Entertainment
Companies from entertainment industry including show business, news and media. The Entertainment theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Entertainment Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.